New drug cocktail aims to deepen remissions in myeloma patients
NCT ID NCT01816971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent complete response). The approach aims to kill more cancer cells by using targeted therapy, immune-modulating drugs, and chemotherapy together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carfilzomib, lenalidomide, and dexamethasone
- What this could lead to
- If successful, this drug combination could improve the chance of achieving a deep remission after stem cell transplant for multiple myeloma.
- What could go wrong
- This is a small, early-phase trial (76 people) with no control group, so results may not apply broadly. Side effects from the drugs and transplant can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber
Boston, Massachusetts, 02215, United States
-
Princess Margaret
Toronto, Ontario, M5T 2M9, Canada
-
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637-1470, United States
-
Washington University in St Louis
St Louis, Missouri, 63130, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.